Evaluation of Mcl-1 Inhibitors in Preclinical Models of Multiple Myeloma

被引：2
|
作者：
Belmonte, Matthew A. [1 ]
Adam, Ammar [1 ]
Borrelli, Deanna [1 ]
Bhavsar, Deepa [1 ]
Bebernitz, Christina [1 ]
Hird, Alexander [1 ]
Secrist, Paul [1 ]
机构：
[1] AstraZeneca, Waltham, MA USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
10.1182/blood.V124.21.3428.3428
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
    Juarez, Dennis
    Buono, Roberta
    Matulis, Shannon M.
    Gupta, Vikas A.
    Duong, Madeleine
    Yudiono, Jacob
    Paul, Madhuri
    Mallya, Sharmila
    Diep, Grace
    Hsin, Peter
    Lu, Alexander
    Suh, Sang Mi
    Dong, Vy M.
    Roberts, Andrew W.
    Leverson, Joel D.
    Jalaluddin, Muhammad
    Liu, Zhuangzhuang
    Bueno, Orlando F.
    Boise, Lawrence H.
    Fruman, David A.
    CANCER RESEARCH COMMUNICATIONS, 2023, 3 (12): : 2497 - 2509
  • [32] Mcl-1 Fragment Mcl-1128-350 Induces Inhibition of Multiple Myeloma Cell Proliferation and Apoptosis
    Podar, K.
    Zimmerhacki, A.
    Zhang, J.
    Tonon, G.
    Barila, D.
    Vallet, S.
    Sattler, M.
    Tai, Y. T.
    Hideshima, T.
    Chauhan, D.
    Anderson, K. C.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S137 - S137
  • [33] Development of Mcl-1 inhibitors for cancer therapy
    Negi, Arvind
    Murphy, Paul, V
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 210
  • [34] Multiple myeloma with amplification of chromosome 1q is highly sensitive to MCL-1 targeting
    Slomp, Anne
    Moesbergen, Laura
    Gong, Jia-nan
    Cuenca, Marta
    Borne, Peter von dem
    Sonneveld, Pieter
    Huang, David
    Minnema, Monique
    Peperzak, Victor
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E49 - E50
  • [35] Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting
    Slomp, Anne
    Moesbergen, Laura M.
    Gong, Jia-nan
    Cuenca, Marta
    von dem Borne, Peter A.
    Sonneveld, Pieter
    Huang, David C. S.
    Minnema, Monique C.
    Peperzak, Victor
    BLOOD ADVANCES, 2019, 3 (24) : 4202 - 4214
  • [36] LOSS OF PRIMING OR MCL-1 DEPENDENCY CONFERRED ACQUIRED RESISTANCE TO VENETOCLAX IN MULTIPLE MYELOMA
    Amiot, M.
    Dousset, C.
    Maiga, S.
    Gomez-Bougie, P.
    Le Coq, J.
    Touzeau, C.
    Moreau, P.
    Le Gouill, S.
    Pellat-Deceunynck, C.
    Moreau-Aubry, A.
    HAEMATOLOGICA, 2016, 101 : 77 - 77
  • [37] Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma
    Ponder, Katelyn G.
    Matulis, Shannon M.
    Hitosugi, Sadae
    Gupta, Vikas A.
    Sharp, Cathy
    Burrows, Francis
    Nooka, Ajay K.
    Kaufman, Jonathan L.
    Lonial, Sagar
    Boise, Lawrence H.
    CANCER BIOLOGY & THERAPY, 2016, 17 (07) : 769 - 777
  • [38] Glutamine Catabolism Maintains MCL-1 Expression in Glucose-Deprived Multiple Myeloma
    Wei, Changyong
    Bajpai, Richa
    Hunter, Alisha D.
    Mahboubi, Darius
    Shanmugam, Mala
    BLOOD, 2017, 130
  • [39] Dual Inhibition Of Mcl-1 By The Combination Of Carfilzomib and TG02 In Multiple Myeloma
    Barnhart, Katelyn G.
    Matulis, Shannon M.
    Hitosugi, Sadae
    Sharp, Cathy
    Burrows, Francis
    Nooka, Ajay K.
    Kaufman, Jonathan L.
    Lonial, Sagar
    Boise, Lawrence H.
    BLOOD, 2013, 122 (21)
  • [40] Rational for a combination of bortezomib and doxorubicin in the treatment of multiple myeloma: A pivotal role for Mcl-1
    Le Gouill, Steven
    Podar, Klaus
    Zhang, Jing
    Hideshima, Teru
    Amiot, Martine
    Dharminder, Chauhan
    Harousseau, Jean-Luc
    Anderson, Kenneth
    BLOOD, 2007, 110 (11) : 449A - 449A
12345